INTRODUCTION IL-1 was described originally as a cytokine, which acts as an endogenous pyrogen with potent, proinflammatory activity. It plays a crucial role in a wide range of host responses to infection and inflammation [1] as well as in the neuronal injury occurring in acute and chronic neurodegenerative disorders [2] . Two separate genes encode for the IL-1␣ and IL-1␤ isoforms, which share a high sequence homology [3] and induce similar effects by binding to the same receptor, i.e., IL-1R Type I (IL-1RI). Upon ligand binding, the IL-1RI forms a signaling heterodimer with the IL-1R accessory protein (IL1RAcP) [4] . IL-1RI and IL-1RAcP belong to the receptor superfamily referred to as the TLR/IL-1R superfamily. In addition to IL-1RI and IL-1RAcP, mammals express at least 11 members (TLR1-11) of this family [5, 6] , which are specialized in the recognition of microbial products, such as the lipid A moiety of Gram-negative bacterial LPS, a ligand of TLR4 [7] , or nonmethylated CpG oligodeoxyribonucleotides, deriving from the bacterial DNA, which binds TLR9 [8] . The highly conserved, cytoplasmic region in the TLR/IL-1R class of receptors, i.e., the Toll/IL-1R translation initiation region (TIR) domain, plays an essential role in signaling downstream of these receptors by recruiting several effectors and favoring their functional interaction. Central to this signaling pathway is the role of adaptor molecules, which bridge the receptors to the protein kinases required to propagate the signal inside the cells [9] . The IL-1R and all of the TLRs with the sole exception of TLR3 use the adaptor protein MyD88 to initiate their signaling pathway [10, 11] . MyD88 is a 33-kDa protein, which contains an N-terminal death domain (DD) and a C-terminal TIR domain separated by a short linker region [12] . MyD88 is recruited to the receptor complexes as a dimer, which is stabilized by homophylic interactions occurring between the DD and TIR domains [13] . Once recruited by the receptor TIR domain, MyD88 associates with the IL-1R-associated kinase 4 (IRAK4) through homophylic interaction between the respective DDs. This event leads to recruitment of another kinase, IRAK1, to the complex and to its phosphorylation/activation by IRAK4 [14] . IRAK1 and IRAK4 then dissociate from the complex, interact with TNF receptor-associated factor 6, another adaptor molecule, and cause the activation of TGF-␤-activated kinase 1. This complex signaling pathway is required to induce the downstream activation of the IB kinase complex and the release of NF-B and for activation of MAPKs p38 and JNK [4, 15] . In addition to MyD88, other adaptor proteins containing a TIR domain have been identified [16] . MyD88 adaptor-like or TIR domain-containing adaptor protein functions downstream of TLR2 and TLR4 [17, 18] . TIR-related adaptor protein inducing IFN (Trif) is recruited by TLR3 and TLR4 and is responsible for activation of IFN-induced genes [19, 20] . Trif-related adaptor molecule (Tram) acts exclusively in the pathway downstream of TLR4 activation and appears to be required to recruit Trif to the receptor [21, 22] .
MyD88-deficient mice are defective in the production of IL-6 and TNF in response to stimulation with IL-1 or other microbial components recognized by TLR2, TLR4, TLR5, and TLR9 [11, 23] . Conversely, it has been demonstrated that the response of macrophages to LPS stimulation of TLR4 is only partly dependent on MyD88, whereas IFN-inducible genes such as glucocorticoid attenuated-response gene 16 or immune-responsive gene 1 are still up-regulated, even in the absence of a functional MyD88 [24] . Thus, this branch of signaling seems to depend on the other adaptor molecules Trif and Tram [16] . Loss of MyD88 expression and/or function has anti-inflammatory effects in several pathological situations such as early artherosclerosis [25] , arthritis [26] , and inflammatory diseases of the CNS such as multiple sclerosis [27] . For this reason, the development of molecules, which interfere specifically with MyD88-dependent signaling, could be useful in the treatment of several immunological disorders [28] . As homodimerization of MyD88 and its interaction with the receptors require the TIR domain, this region is targeted for studies aimed at developing drugs, which can block MyD88 activation [29, 30] . Our laboratory previously identified a heptapeptide, which mimics the BB-loop of the conserved TIR domain of MyD88. This peptide interferes strongly with dimerization of MyD88 and activation of the IL-1 signaling pathway in live cells [31] . It is interesting that site-directed mutagenesis of three charged residues within this heptapeptide also caused loss of homodimerization, interaction with the receptor, and IL-1␤ signaling [32] , thus confirming our results through a different approach. Herein, we report the identification and characterization of a novel compound (ST2825), which mimics this MyD88 BB-loop heptapeptide and has biological activity toward this adaptor protein. Our studies suggest that this newly synthesized compound has potential as an anti-inflammatory drug.
MATERIALS AND METHODS

Synthesis of ST2825
The peptidomimetic ST2825 was synthesized as described previously in Patent No. WO 200606709 [33] .
Plasmids
Hemagglutinin (HA)-tagged DD of MyD88-expressing plasmid was a kind gift from Dr. Marta Muzio ("Mario Negri" Institute, Milan, Italy). Expression vectors for Flag-tagged MyD88 or Myc-tagged MyD88 were constructed by inserting PCR-generated cDNA fragments in the mammalian expression vectors p3X-Flag or pCDNA 3 -N 2 -Myc, respectively. For the NF-B reporter assays, the NF-B luciferase and Renilla luciferase constructs were used according to the manufacturer's instructions (Promega, Madison, WI, USA).
Cell culture and transfections
The human embryonic kidney (HEK)293T and HeLa cell lines were cultured in DMEM, supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA), and grown in a 37°C humidified atmosphere of 5% CO 2 . For coimmunoprecipitation of Flag-MyD88/Myc-MyD88, HEK293T cells were cultured in 10 cmdiameter dishes and transfected by the calcium-phosphate method with 4 -5 g of the appropriate plasmids. The peptidomimetic compound ST2825 was added to the medium 7 h after transfection. To detect Flag-MyD88 associated with HA-MyD88Death, Myc-IRAK1 kinase death (KD), Myc-MyD88TIR, or Myc-IRAK4KD, HEK293T cells were cultured in 6 cm-diameter dishes and transfected by Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The peptidomimetic compound ST2825 was added to the medium 6 h after transfection.
For mitogenic stimulation, Hela cells were starved overnight in medium without serum, pretreated for 15 min with or without various concentrations of ST2825 prior to stimulation in the presence or absence of 100 nM epidermal growth factor (EGF; PeproTech, Rocky Hill, NJ, USA) for various times. At the end of stimulation, cells were washed with 2 ml ice-cold PBS and lysed in 80 l buffer [50 mM HEPES, pH 7.4, 15 mM MgCl 2 , 150 mM NaCl, 15 mM EGTA, 10% glycerol, 1% Triton X-100, protease inhibitor cocktail (SigmaAldrich, St. Louis, MO, USA), 20 mM ␤-glycerophosphate, 2 mM DTT, 1 mM Na 3 VO 4 ]. Cells were pelleted by centrifugation at 10,000 g for 10 min, and the resulting supernatants were diluted in SDS sample buffer for Western blot analysis of levels of phospho (p)ERK1/2.
Cell viability assay
Cell viability was assessed by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) staining according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN, USA), measuring the reaction product with a spectrophotometer (absorbance at 450 nm). Briefly, HeLa cells were seeded at 10 5 cells/ml in a 96-well tissue-culture plate. After incubating overnight, the medium was discarded, and the cells were added with tissue culture medium, 10% FBS, containing ST2825 (previously dissolved in DMSO) at concentrations ranging from 0.1 to 10 M and DMSO at 0.1% final concentration. The cells were incubated for 6 and 18 h and then added with the yellow XTT (0.3 mg/ml) for further 2 h of incubation. At the end of the incubation periods, reactions were quantified by using a Sirio S Seac microplate reader (Radim S.p.A., Pomezia, Italy).
Coimmunoprecipitation assay
HEK293T cells were collected 20 h after transfection, washed in ice-cold PBS, and lysed in buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 20 mM ␤-glycerophosphate, 2 mM DTT, 1 mM Na 3 VO 4 , and protease inhibitors. After 10 min on ice, cell lysates were centrifuged at 10,000 g for 10 min at 4°C, and cytosolic fractions were collected for immunoprecipitation. Cell extracts (1 mg total proteins) were precleared by incubation for 1 h with protein G-Sepharose beads (Sigma-Aldrich) under constant shaking at 4°C. After preclearing, cell extracts were incubated with 2 g mouse anti-Flag M2 (Sigma-Aldrich) for 1 h under constant shaking at 4°C. Concurrently, protein G-Sepharose beads were presaturated with 0.1% BSA (Sigma-Aldrich) in PBS in the same conditions for 1 h. After incubation, the beads were washed twice with lysis buffer and then incubated with cell extracts containing the antibody for 1 h further at 4°C under constant shaking. Sepharose bead-bound immunocomplexes were washed three times in lysis buffer and eluted in SDS-PAGE sample buffer for Western blot analysis.
Western blot analysis
Cell extracts or immunoprecipitated proteins were diluted in SDS sample buffer as described above and boiled for 5 min. Proteins were separated on A 8 -12% SDS-PAGE gel and transferred to polyvinylidene fluoride Immobilon-P membranes (Millipore, Bedford, MA, USA) using a semidry blotting apparatus (Bio-Rad, Hercules, CA, USA). Membranes were saturated with 5% nonfat dry milk in PBS containing 0.1% Tween 20 for 1 h at room temperature and incubated overnight at 4°C with the following primary antibody (1:1000 dilution): mouse anti-HA (Berkeley Antibody Company, Babco, Richmond, CA, USA), mouse anti-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-Flag M2 (Sigma-Aldrich), and rabbit anti-pERK1/2 (Cell Signaling Technology, Beverly, MA, USA). Secondary anti-mouse IgGs conjugated to HRP (Amersham Biosciences, Little Chalfont, UK) were incubated with the membranes for 1 h at room temperature at a 1:10,000 dilution in PBS containing 0.1% Tween 20. Immunostained bands were detected by the chemiluminescence method (Santa Cruz Biotechnology).
NF-B reporter assay
HeLa cells (1ϫ10 5 ) were cultured in 12-well plates and transfected with 0.5 g of a NF-B-dependent luciferase reporter gene and R. luciferase reporter gene (4 ng) as an internal control using the FuGENE 6 reagent (Roche Diagnostic, Nutley, NJ, USA) according to the manufacturer's instructions. Twenty-four hours after transfection, cells were placed in medium without serum for 2 h and pretreated with or without various concentrations of ST2825 for 15 min prior to stimulation in the presence or absence of IL-1␤ (30 ng/ml; R&D Systems, Minneapolis, MN, USA) or polyinosinic:polycytidylic [poly(I:C); 100 g/ml; Invivogen, San Diego, CA, USA] for an additional 30 min. After rinsing with PBS, cells were incubated with medium without serum for 3 h, then harvested, lysed, and analyzed using a biocounter luminometer as described elsewhere [31] . Data were normalized for transfection efficiency, dividing firefly luciferase activity by that of R. luciferase. Data are expressed as mean-fold induction Ϯ SD from a minimum of three separate experiments.
In vivo effect of ST2825 on IL-1␤ response
Mice (female C57Bl/6 purchased from Harlan, Indianapolis, IN, USA) were divided into experimental groups of 15 mice. They were injected i.p. with saline (control animals) or recombinant murine IL-1␤ (20 g/Kg). A timecourse analysis of IL-6 production established that the peak of cytokine was reached 2 h after IL-1␤ injection. ST2825, administered orally as 0.5% suspension in carboxymethylcellulose (CMC) or CMC alone, was supplied to the experimental mice groups. Two hours after IL-1␤ injection, the animals were killed, and sera were collected to assay IL-6 levels. Mice, which were treated orally with 100 and 200 mg/Kg ST2825, showed lower levels of IL-6 versus CMC-treated mice (PϽ0.01; data were evaluated with one-way ANOVA followed by Dunnett's t-test).
PBMC proliferation assay
Venous blood was obtained from healthy donors from the Ospedale Pediatrico Bambino Gesù (Rome, Italy) after informed consensus. Human PBMC were isolated by Ficoll-Paque TM Plus (Amersham Pharmacia Biotech, Little Chalfont, UK) density-gradient centrifugation. The lymphocyte-enriched buffy coat was removed and washed in PBS. PBMC were labeled with 5-chloromethylfluorescein diacetate (CMFDA) at the final concentration of 0.1 g/ml (CellTracker CMFDA, Molecular Probes, Eugene, OR, USA), seeded at the concentration of 5 ϫ 10 5 cells/well in 96-well plates (Becton Dickinson, San Jose, CA, USA), and cultured with 200 l complete RPMI 1640 (Invivogen), supplemented with 10% FCS (Hyclone Laboratories, Logan, UT, USA). ST2825 was added to the medium at the indicated concentrations in the presence or absence of human CpG oligodeoxynucleotides (ODN 2006, Hycult Biotechnology, The Netherlands), used at the optimal concentration of 2.5 g/ml. Cell proliferation was measured on Day 7 by FACSCalibur flow cytometer (Becton Dickinson) interfaced to a Macintosh CellQuest computer program. Thirty thousand events were analyzed whenever possible. To identify B cell subsets, antibodies to CD19, CD27, and CD38 (Becton Dickinson) were used.
ELISA immunoassay
Secreted Igs were detected at Day ϩ7 by ELISA assay. Briefly, 96-well plates (Corning Inc., Corning, NY, USA) were coated overnight with purified goat anti-human IgA ϩ IgG ϩ IgM (Jackson ImmunoResearch, West Grove, PA, USA). After washing with PBS containing 0.05% Tween and blocking with PBS containing 1% gelatin (1 h, room temperature), plates were incubated for 1 h at 37°C with the supernatants of the cultured cells. After washing, plates were incubated for 1 h with peroxidase-conjugated fragment goat anti-human IgA,IgG, and IgM antibodies (Jackson ImmunoResearch). O-Phenylendiamine tablets (Sigma-Aldrich) were used as chromogenic substrate. OD was measured at 405 nm, and concentrations were calculated by interpolation from the standard curve.
RESULTS
ST2825 interferes with MyD88 homodimerization in a TIR-dependent manner
We reported previously that a peptide within the BB-loop region of the TIR domain of MyD88 (196 -202) inhibits MyD88 homodimerization and downstream activation of NF-B in response to IL-1 stimulation [31] . On the basis of the structure of this heptapeptide, a series of synthetic molecules was produced and screened for biological activity toward MyD88 signaling [33] . Among the molecules initially screened, ST2825 (Fig. 1A) appeared to possess the ability to interfere with IL-1␤-induced activation of NF-B (Fig. 1C) . By contrast, this molecule did not interfere with activation of NF-B induced by poly(I:C), a ligand that stimulates the MyD88-independent TLR3 (Fig. 1D) , nor with EGF-mediated activation of the MAPKS ERK1/2 in HeLa cells (Fig. 1E) . As shown in Figure  2 , incubation of HeLa cells with ST2825 for 6 or 18 h did not strongly affect cell viability (13% decrease at 6 h and 16% at 18 h for the maximal dose used).
ST2825 was modeled on the structure of the consensus peptide in the BB-loop of the TIR domain of MyD88, as illustrated in Figure 1B , to mimic the ␤-turn portion (yellow), the hydrophobic portion (gray), and the charged portion (blue). It is important that this last polar portion efficaciously superimposed to the aliphatic chain of Arg196. To test whether the effect of ST2825 on IL-1␤ signaling was a result of interference with its putative target MyD88, we used a coimmunoprecipitation test to determine the extent of MyD88 homodimerization [31] . HEK293T cells were cotransfected with vectors for the expression of MyD88 containing a Flag or a Myc epitope tag. Cell extracts were immunoprecipitated with a Flag antibody, and dimerization was tested by the presence of Myc-MyD88 in the immunoprecipitates. When Flag-MyD88 and Myc-MyD88 were coexpressed in HEK293T cells, they were able to homodimerize, as demonstrated by this coimmunoprecipitation assay (Fig. 3A, Lane 2) , whereas in the absence of FlagMyD88, the Myc-MyD88 protein could not be detected in the immunoprecipitates (Fig. 3A, Lane 1) . ST2825 inhibited this interaction in a concentration-dependent manner with ϳ40% inhibition of dimerization at 5 M ST2825 and 80% inhibition at 10 M ST2825 (Fig. 3A, Lanes 3 and 4) . Figure 3B shows the quantitative data of three experiments.
To determine whether ST2825 specifically inhibited homodimerization of MyD88 TIR domains without affecting homodimerization of the DDs, we performed coimmunoprecipitation experiments of full-length MyD88 with its isolated domains. Flag-MyD88 and HA-MyD88-DD (Fig. 4A) or MycMyD88-TIR (Fig. 4B) were coexpressed in the presence or absence of ST2825 (5 or 10 M) in HEK293T cells, and association was determined by coimmunoprecipitation. FlagMyD88 interacted specifically with HA-MyD88-DD (Fig. 4A , Lane 2) and Myc-MyD88-TIR (Fig. 4B, Lane 2) ; however, ST2825 affected only association with the TIR domain, without interfering with recruitment of the DD (Fig. 4, A and B, Lanes 3 and 4). These results indicate that the target of ST2825 is the MyD88 TIR/TIR homophylic interaction.
ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88
Dimerization of MyD88 is required for its recruitment to the plasma membrane and the ensuing activation of the downstream kinases IRAK1 and IRAK4 [14, 34] . The interaction between IRAKs and MyD88 is transient, and IRAK1 readily dissociates after being phosphorylated by IRAK4. However, this interaction can be stabilized by blocking the kinase activity of IRAKs in their KD derivatives [35] . Hence, we set out to determine the effect of ST2825 on the recruitment of IRAK1KD and IRAK4KD by MyD88 using a coimmunoprecipitation assay. Flag-MyD88 and Myc-IRAK1KD (Fig. 5A) or Myc-IRAK4KD (Fig. 5B) , coexpressed in HEK293T cells, interacted strongly in this assay (Fig. 5, A and B, Lanes 2) . By contrast, treatment of cells with 10 M ST2825, which causes a 70% inhibition of MyD88 homodimerization (Fig. 3B) , suppressed this interaction almost completely (Fig. 5, A and B, Lanes 3). As ST2825 does not affect dimerization of DDs (Fig.  4A) , the experiment indicates that this compound inhibits the recruitment of IRAKs as a consequence of its interfering effect on MyD88 homodimerization.
ST2825 inhibits IL-1␤-dependent production of IL-6 in vivo
To determine whether ST2825 was also able to counteract IL-1 signaling in vivo, we assessed its effects on IL-1␤-dependent production of IL-6 in mice. The animals were administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/Kg, 5 min prior to i.p. injection with 20 g/Kg IL-1␤. As shown in Figure 6 , ST2825 exerted a significant inhibition (PϽ0.01) of IL-1␤-stimulated production of IL-6 at 100 and 200 mg/Kg.
ST2825 inhibits B cell proliferation and differentiation in response to TLR9 stimulation
To test the activity of ST2825 in a different setting, in which MyD88 is required, we assayed the response to TLR9 stimulation in human B cells. The interaction of TLR9 with its ligand CpG activates a MyD88-dependent signal transduction pathway [6] . In humans, TLR9 is mainly expressed in B cells and in plasmacytoid dendritic cells. B cells respond to TLR9 stimulation by proliferating and differentiating into plasma cells (CD27 bright CD38 pos cells) [36] . We measured cell proliferation using CMFDA, a cytoplasm fluorescent marker, which enters all viable cells and is diluted progressively into the daughter cells after each cell division [37] . CMFDA-labeled PBMC were cultured for 7 days with increasing concentrations of ST2825 in the presence or absence of CpG. Stimulation of TLR9-induced B cell proliferation, identified as CD27 bright , and the effect elicited by CpG were inhibited by ST2825 at 4 M and blocked completely at 8 M (Fig. 7A) . Cell viability was not affected at these concentrations, as determined by measuring the number of B cells present in the population of total PBMC at the end of incubations, in the presence or absence of 4 and 8 M ST2825, whereas a minor effect was obtained with the higher dose (16 M; Fig. 7B ). ST2825 also inhibited the generation of plasma cells induced by CpG treatment. The effect was concentration-dependent, with no significant effect at 1 M and a complete lack of plasma cell differentiation (identified as CD27 bright CD38 pos cells in Fig.  7A ) at 8 and 16 M (Fig. 7C ). In agreement with the effect on plasma cell differentiation, ST2825 (8 M) abolished antibody secretion in the culture supernatants as measured by ELISA in all three patients examined (Fig. 7D) .
These results indicate that ST2825 inhibits TLR9-triggered MyD88 signaling in primary cultures of human B cells. 
DISCUSSION
MyD88 is an adaptor protein essential for the intracellular signaling in response to IL-1␤ and TLR9 stimulation. Although activation of these receptors is required for an efficient defense response to pathogenic infection, their excessive signaling can lead to clinical syndromes [38, 39] . Hence, limiting MyD88-mediated signaling might be beneficial in the treatment of pathological, inflammatory situations. Herein, we describe a novel, synthetic compound (ST2825), which interferes with MyD88 signaling in vitro and in vivo. Using coimmunoprecipitation experiments, luciferase reporter assays, FACS analysis, and ELISA, we demonstrate that ST2825 has the potential to suppress an inflammatory response to IL-1R and TLR9 stimulation, suggesting that the approach used in our work could be useful to develop compounds that exert anti-inflammatory actions [40] .
Proper and adequate TLR/IL-1R signaling is essential for microbial recognition, inflammation, microbial clearance, and cell death [41] . However, hyperactivation of TLR/IL-1R signaling may cause septic shock and autoimmune disorders, and an ineffective or inappropriate response might favor diseases such as cancer and allergy [42] . Recent studies have shown how these signaling pathways are tightly regulated in inflammatory cells. Indeed, a panoply of antagonistic factors exists in inflammatory cells to ensure the appropriate modulation of TLR/IL-1R signaling [43, 44] . For instance, ST2 [45] , RP105 [46] , and SIGIRR [47] are membrane-bound orphan receptors that function as negative regulators for TIR-mediated signaling. Many physiological antagonists of TLR/IL-1R signaling act at the intracellular level, such as IRAKM [48] , a splice variant of IRAK2 [49] , MyD88s, a splice variant of MyD88 [50] , PI-3K [51] , suppressor of cytokine signaling 3 [52] , A20 [53] , and Triad3A, a member of the Triad3 family of RING finger E3 ubiquitin ligases [54] . The abundance of endogenous, negative regulators highlights the necessity to control proper activation of this pathway in inflammatory cells. Nevertheless, uncontrolled activation still occurs in several pathological situations, indicating the requirement for synthetic, therapeutic inhibitors.
The remarkable progress in the elucidation of TLR signaling has drawn a keen interest toward TLR-targeted therapeutics from pharmaceutical companies [55, 56] . Indeed, agonists and antagonists of IL-1R/TLR signaling can find therapeutic application depending on the clinical setting. Activators may have adjuvant roles, thus improving vaccine efficacy and reinforcing the immune response to cancer, and inhibitors may help to dampen inflammation in disorders such as allergy, atherosclerosis, and autoimmune diseases [57] .
MyD88 is a suitable target for drugs aimed at inhibiting exogenous and endogenous activation of TLR/IL-1R signaling [16] . Rebek Jr. and colleagues [29] first synthesized and proved the in vivo efficacy of a low molecular weight MyD88 inhibitor by modeling a tripeptide sequence of the BB-loop of the TIR domain and subsequently, described bifunctional TIR mimetic compounds capable of disrupting the interaction of MyD88 with the IL-1R/IL-1RAcP complex [30] . In a previous investigation, our group showed that self-association of MyD88 could be interfered specifically by a heptapeptide targeting the BB-loop [31] . The synthetic compound ST2825 was modeled after this sequence (RDVLPGT) of MyD88. Herein, by using several approaches, we show that ST2825 interferes efficiently with MyD88 homodimerization and with IL-1␤-and CpGdriven signaling in distinct experimental settings.
The target of ST2825 is likely the interface between the BB-loops of MyD88 TIR domains [31] . As MyD88 dimerizes through homophylic interactions between the DD and the TIR domains, it was important to determine whether ST2825 required the TIR domain to exert its effect. The dimerization assays with the isolated TIR or DD domain and full-length MyD88 presented here demonstrate that ST2825 interferes only with the association between full-length MyD88 and the TIR domain, without affecting dimerization with the DD domain of the protein. This result indicates that ST2825 recognizes the target after which it was modeled.
Using the coimmunoprecipitation approach, we also showed that ST2825 prevents the recruitment of IRAK1 and IRAK4 by MyD88. As ST2825 has no effect on dimerization of MyD88 DD domains, these results suggest that MyD88 homodimerization is a prerequisite for the recruitment of IRAKs and that ST2825 interferes with these events by preventing TIR domain homophylic interactions between MyD88 molecules. The addition of ST2825 attenuates the activation of NF-B in HeLa cells stimulated with IL-1␤. It is more important that orally administered ST2825 attenuated the production of IL-6 induced by IL-1␤ injection in mice. This result suggests that ST2825 is also effective in an in vivo model of acute inflammation. However, given the moderate effect on IL-6 production, it remains to be evaluated whether ST2825 may confer clinical advantages.
It is remarkable that we found that ST2825 also inhibited signaling effectively from the TLR9 ligand CpG, which operates in the endosomal compartment. This receptor depends strictly on MyD88 for signal transduction [2] . CpG-containing DNAs are internalized rapidly by immune cells and then interact with TLR9 present in endocytic vesicles [58] . TLR9 activation triggers a MyD88-dependent response in B cells, which undergo proliferation, class switching, and differentiation into antibody-secreting plasma cells [58] . In B cells, this activation is enhanced by simultaneous signals delivered through the antigen receptor. It has been shown that coactivation of naive B cells by TLR9 and the B cell antigen receptor drives their differentiation to plasma cells, whereas TLR9 alone is sufficient for memory B cell activation and differentiation into plasma cells [36] . In our experimental setting, we observed that CpG induced extensive proliferation of memory B cells, differentiation into plasma cells, and secretion of antibodies of all isotypes in the culture supernatants. It is striking that ST2825 suppressed all these events. The effect was dose-dependent, within the same range of the concentrations required to interfere with MyD88 homodimerization and downstream events, and did not produce toxic effects on cell survival. As TLR9 antagonists have already demonstrated their beneficial effects in murine models of systemic lupus erythematosus and rheumatoid arthritis [59, 60] , our studies suggest that ST2825 may be useful in the treatment of these autoim- Fig. 6 . ST2825 attenuates IL-1␤-stimulated IL-6 production in vivo. Two groups of control mice and three groups of treated mice were injected with 20 g/Kg IL-1␤. Vehicle CMC (control groups) or different doses of ST2825 were administered orally before IL-1␤ injection. Two hours after injection, mice were killed, and IL-6 production was measured by ELISA in the collected sera. Statistical analyses of the data were performed using the one-way ANOVA followed by Dunnett's t-test. mune diseases. Future experiments will be aimed at testing the efficacy and the side-effects of ST2825 in murine models of immunological disorders. 
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